Six Month Clinical Trial Assessing Efficacy and Safety of Inhaled Insulin in Type 1 Diabetes
Public ClinicalTrials.gov record NCT00424333. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Efficacy and Safety of Inhaled Compared With Subcutaneous Human Insulin in an Intensive Insulin Regimen for Subjects With Type 1 Diabetes Mellitus: A Six-Month, Outpatient, Parallel Comparative Trial
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
To determine in subjects with Type 1 Diabetes Mellitus: 1. Whether glycemic control can be achieved at least as effectively with a) an intensive insulin regimen involving pre-meal inhaled insulin plus twice daily subcutaneous NPH insulin as with b) an intensive subcutaneous insulin regimen involving pre-meal regular insulin plus twice daily NPH, given as 4 injections per day. The treatment regimens differ only by the route of delivery of the short acting insulin. 2. The toleration and safety of inhaled insulin therapy and its effects after 6months, if any, on measures of pulmonary function.
Study identification
- NCT ID
- NCT00424333
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 320 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 12 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 1999 (Type not available)
- Primary completion
- Not listed
- Completion
- Oct 2000 (Type not available)
- Last update posted
- Feb 13, 2007
1999 – 2000
United States locations
- U.S. sites
- 30
- U.S. states
- 17
- U.S. cities
- 30
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pfizer Investigational Site | Duarte | California | — | — |
| Pfizer Investigational Site | Long Beach | California | — | — |
| Pfizer Investigational Site | Los Angeles | California | — | — |
| Pfizer Investigational Site | Stanford | California | — | — |
| Pfizer Investigational Site | Denver | Colorado | — | — |
| Pfizer Investigational Site | New Haven | Connecticut | — | — |
| Pfizer Investigational Site | Gainesville | Florida | — | — |
| Pfizer Investigational Site | Hollywood | Florida | — | — |
| Pfizer Investigational Site | Miami | Florida | — | — |
| Pfizer Investigational Site | Tallahassee | Florida | — | — |
| Pfizer Investigational Site | Peoria | Illinois | — | — |
| Pfizer Investigational Site | Skokie | Illinois | — | — |
| Pfizer Investigational Site | Lutherville | Maryland | — | — |
| Pfizer Investigational Site | Waltham | Massachusetts | — | — |
| Pfizer Investigational Site | Minneapolis | Minnesota | — | — |
| Pfizer Investigational Site | Columbia | Missouri | — | — |
| Pfizer Investigational Site | New Hyde Park | New York | — | — |
| Pfizer Investigational Site | Rochester | New York | — | — |
| Pfizer Investigational Site | Syracuse | New York | — | — |
| Pfizer Investigational Site | The Bronx | New York | — | — |
| Pfizer Investigational Site | Durham | North Carolina | — | — |
| Pfizer Investigational Site | Winston-Salem | North Carolina | — | — |
| Pfizer Investigational Site | Portland | Oregon | — | — |
| Pfizer Investigational Site | Pittsburgh | Pennsylvania | — | — |
| Pfizer Investigational Site | Dallas | Texas | — | — |
| Pfizer Investigational Site | Houston | Texas | — | — |
| Pfizer Investigational Site | Burlington | Vermont | — | — |
| Pfizer Investigational Site | Charlottesville | Virginia | — | — |
| Pfizer Investigational Site | Charlottsville | Virginia | — | — |
| Pfizer Investigational Site | Seattle | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 5 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00424333, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 13, 2007 · Synced Oct 30, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00424333 live on ClinicalTrials.gov.